

S/N 08/927,939



PATENT
REC'D

DEC 15 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David J. Grainger et al.

Examiner: Prema Mertz

Serial No.: 08/927,939

Group Art Unit: 1646

Filed: September 11, 1997

Docket: 295.022US1

TECH CENTER 16C

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN
INFLAMMATORY RESPONSE

PRELIMINARY AMENDMENT

Box CPA
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant has carefully reviewed the final Office Action mailed November 12, 1999 and the Advisory Action mailed May 22, 2000. Detailed comments in response to the final Office Action and Advisory Action are found below. Please amend the specification as follows:

In the Claims

Please amend the claims as follows:

Sub E1
D1
(Twice amended) An isolated and purified peptide of a chemokine, a variant, or a derivative thereof, comprising no more than 30 amino acid residues, wherein at least three contiguous residues of the peptide correspond to residues in the carboxyl-terminal half of the mature form of the chemokine, wherein the three contiguous residues correspond to residues Trp-Val-Gln or Lys-Gln-Lys in human MCP-1, and wherein the peptide inhibits the activity of the corresponding native chemokine.

D2 10. (Amended) The peptide of claim 8 wherein the CXC chemokine is IL-8[, IP-10, SDF-1, PF-4, NAP-2, GRO α , GRO β , GRO γ , NAP-2 or ENA78].

D3 11. (Twice amended) A cyclic reverse [D] sequence [(CRD)] derivative (CRD) of a peptide of a chemokine or a variant thereof.

Sub E2
D4 42. (Amended) The peptide of claim 4 which is Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln [(SEQ ID NO:7)].